|
|
| (439 intermediate revisions by 28 users not shown) |
| Line 1: |
Line 1: |
| '''Do Not Delete'''
| | {{ACM}} {{SemRikken}} |
|
| |
|
|
| |
|
| | | ''SANDBOX'' |
| | | [[File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png]] |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:GreenYellow"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| |bgcolor="GreenYellow" |'''a.''' LDL-C should be <100 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |'''b.''' If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |'''c.''' If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |'''d.''' If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''e.''' Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |'''f.''' If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C]])
| |
| | |
| |}
| |
| | |
| ==== [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] ====
| |
| | |
| '''a.''' Reduction of LDL-C to <70 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:A]])
| |
| | |
| '''b.''' If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| | |
| '''c.''' If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| | |
| '''d.''' Therapeutic options to reduce non HDL - C are [[Niacin]] (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| | |
| '''e.''' Therapeutic options to reduce non HDL - C are [[Fibrate]] therapy (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| | |
| | |
| | |
| | |
| | |
| ----
| |
| {| class="infobox" style="float:right;" align="center"
| |
| |-
| |
| | [[File:Siren.gif|30px|link=Acute coronary syndrome intern survival guide]]
| |
| | [[Acute coronary syndrome intern survival guide|Intern <br> Survival <br> Guide]]
| |
| |}
| |
| | |
| {{clr}}
| |
| | |
| {| class="infobox" style="float:right;"
| |
| |-
| |
| | [[File:Siren.gif|30px|link=Acute coronary syndrome intern survival guide]]
| |
| {| border="0px" |
| |
| | [[Acute coronary syndrome intern survival guide|Intern <br> Survival <br> Guide]]
| |
| |}
| |
| |}
| |
| | |
| {{clr}}
| |
| {| class="infobox" style="float:right;"
| |
| |-
| |
| | [[File:Siren.gif|30px|link=Acute coronary syndrome intern survival guide]]|| <br> || <br>
| |
| | [[Acute coronary syndrome intern survival guide|Intern <br> Survival <br> Guide]]
| |
| |}
| |
| | |
| {| class="infobox" style="float:right;" align="center"
| |
| |-
| |
| | [[File:Siren.gif|30px|link=Acute coronary syndrome intern survival guide]]
| |
| {| border="0px" |
| |
| | [[Acute coronary syndrome intern survival guide|<font size="1">Intern Survival Guide</font> ]]
| |
| |}
| |
| |}
| |
| | |
| {{clr}}
| |
| {| class="infobox" style="float:right;" align="center"
| |
| |-
| |
| | <br><br><font size="1"> I</font> <br> <font size="1"> n</font> <br> <font size="1"> t</font> <br> <font size="1"> e</font> <br> <font size="1"> r</font> <br> <font size="1"> n</font> ||<br> || [[File:Siren.gif|90px|link=Acute coronary syndrome intern survival guide]]|| <br> || <br><font size="1"> S<br> u<br> r<br> v<br> i<br> v<br> a<br> l</font> || <br>
| |
| |-align="center"
| |
| | <br> || <br> || <font size="1"> G u i d e </font> || <br> || <br>
| |
| |}
| |
| | |
| {{clr}}
| |
| | |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:SteelBlue"| Important
| |
| |-
| |
| | Follow up with all pending tests and lab results as soon as these become available. For information on evaluating the results go to the apppropriate section on this page.
| |
| |-
| |
| |}
| |
_9.33.11_p.m..png)